Axonics Inc (AXNX) Stock Price & Overview
NASDAQ:AXNX • US05465P1012
The current stock price of AXNX is 70.98 USD. Today AXNX is up by 0.75%. In the past month the price increased by 0.97%. In the past year, price increased by 26.1%.
AXNX Key Statistics
- Market Cap
- 3.628B
- P/E
- N/A
- Fwd P/E
- 81.39
- EPS (TTM)
- -0.01
- Dividend Yield
- N/A
AXNX Stock Performance
AXNX Stock Chart
AXNX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AXNX. When comparing the yearly performance of all stocks, AXNX turns out to be only a medium performer in the overall market: it outperformed 65.53% of all stocks.
AXNX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AXNX. While AXNX has a great health rating, there are worries on its profitability.
AXNX Earnings
AXNX Forecast & Estimates
19 analysts have analysed AXNX and the average price target is 73.33 USD. This implies a price increase of 3.31% is expected in the next year compared to the current price of 70.98.
For the next year, analysts expect an EPS growth of 56.54% and a revenue growth 23.72% for AXNX
AXNX Groups
Sector & Classification
AXNX Financial Highlights
Over the last trailing twelve months AXNX reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS decreased by -116.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.73% | ||
| ROE | -0.85% | ||
| Debt/Equity | 0 |
AXNX Ownership
AXNX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.7 | 197.553B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.03 | 176.649B | ||
| SYK | STRYKER CORP | 25.26 | 147.075B | ||
| BSX | BOSTON SCIENTIFIC CORP | 20.62 | 109.521B | ||
| IDXX | IDEXX LABORATORIES INC | 43.78 | 50.748B | ||
| BDX | BECTON DICKINSON AND CO | 10.88 | 49.634B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.66 | 49.488B | ||
| RMD | RESMED INC | 21.1 | 37.626B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.73 | 35.608B | ||
| DXCM | DEXCOM INC | 28.87 | 28.503B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.18 | 19.416B | ||
| PODD | INSULET CORP | 38.31 | 17.013B | ||
| HOLX | HOLOGIC INC | 15.04 | 16.846B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AXNX
Company Profile
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 797 full-time employees. The company went IPO on 2018-10-31. The firm has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. The company engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Company Info
Axonics Inc
26 Technology Drive
Irvine CALIFORNIA 92618 US
CEO: Raymond W. Cohen
Employees: 797
Phone: 19493966322
Axonics Inc / AXNX FAQ
What does AXNX do?
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 797 full-time employees. The company went IPO on 2018-10-31. The firm has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. The company engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Can you provide the latest stock price for Axonics Inc?
The current stock price of AXNX is 70.98 USD. The price increased by 0.75% in the last trading session.
Does Axonics Inc pay dividends?
AXNX does not pay a dividend.
What is the ChartMill technical and fundamental rating of AXNX stock?
AXNX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Which stock exchange lists AXNX stock?
AXNX stock is listed on the Nasdaq exchange.
How is the market expecting AXNX stock to perform?
19 analysts have analysed AXNX and the average price target is 73.33 USD. This implies a price increase of 3.31% is expected in the next year compared to the current price of 70.98.